Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 23, 2022
Event: Entry into a Material Definitive Agreement (Purchase Agreement) with Lincoln Park Capital Fund, LLC.
Key Financial Metrics and Transaction Terms
- Capital Commitment: Lincoln Park committed to purchase up to $15.0 million of the Company's common stock.
- Commitment Fee: The Company issued 123,609 shares of Common Stock to Lincoln Park as an upfront commitment fee.
- Issuance Cap (Exchange Cap): The aggregate number of shares issuable is capped at 3,142,430 shares, representing 19.99% of outstanding shares prior to execution, unless shareholder approval is obtained or specific pricing thresholds are met.
- Beneficial Ownership Limit: Sales are restricted if they would result in Lincoln Park beneficially owning more than 9.99% of outstanding shares.
- Purchase Mechanics:
- Regular Purchase: Up to 25,000 shares per notice (increasable to 75,000 shares based on price thresholds), with a maximum single purchase obligation of $1,250,000.
- Accelerated Purchases: Additional shares may be purchased if the maximum Regular Purchase amount is directed.
- Pricing: Based on prevailing market prices immediately preceding the sale; no upper price limit.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Agreements
The filing discloses the execution of a Purchase Agreement and a Registration Rights Agreement. Key terms include:
- Termination Rights: The Company may terminate the agreement at any time at its sole discretion without cost or penalty by providing one business day's notice.
- Short Selling Restrictions: Lincoln Park is covenanted not to engage in direct or indirect short selling or hedging of the Common Stock.
- Registration: Shares are registered under the Company's effective shelf registration statement on Form S-3 (File No. 333-257558).
- Conditions Precedent: Sales commence only after delivery of a prospectus supplement and receipt of customary legal opinions, anticipated around March 23, 2022.
Guidance, Outlook, and Risks
- Management Commentary: The Company may deliver purchase notices subject to market conditions and capital needs. There are no financial or business covenants, restrictions on future financings (other than variable rate transaction restrictions), or rights of first refusal in the agreement.
- Risks and Contingencies:
- Dilution of existing shareholders due to the issuance of up to 19.99% of outstanding shares.
- Market price volatility affecting the number of shares issued for a fixed dollar amount.
- Reliance on the Company's discretion to initiate purchases; Lincoln Park has no obligation to purchase unless directed.
- Unusual Items: The filing explicitly states that the agreement contains no penalties, liquidated damages, or limitations on the use of proceeds.
Investor Verification Checklist
- Verify the current outstanding share count to calculate the precise dilution impact of the 3,142,430 share cap.
- Review the prospectus supplement (to be filed) for specific pricing formulas and threshold prices for Regular and Accelerated Purchases.
- Monitor subsequent filings to determine if the Company has issued any purchase notices under the agreement.
- Check for any shareholder approval votes regarding the issuance of shares exceeding the 19.99% Exchange Cap.
- Confirm the Company's current cash position and working capital needs to assess the likelihood of utilizing the full $15.0 million commitment.